Meeting
2012 ASCO Annual Meeting
Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).
Authors
Ines Maria Vaz Duarte Luis
Dana-Farber Cancer Institute, Boston, MA
Ines Maria Vaz Duarte Luis , Rebecca A Ottesen , Melissa E Hughes , P. Kelly Marcom , Beverly Moy , Hope S. Rugo , Richard L. Theriault , John Wilson , Joyce C. Niland , Jane C. Weeks , Nancy U. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 30, 2012 (suppl; abstr 599)
DOI
10.1200/jco.2012.30.15_suppl.599
Abstract #
599
Poster Bd #
9B
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao
Poster
2016 ASCO Annual Meeting
Outcomes of single versus double hormone receptor positive breast cancer.
First Author: Josee-Lyne Ethier
Poster
2015 ASCO Annual Meeting
Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.
First Author: Antonino Musolino
Poster
2012 ASCO Annual Meeting
Estrogen receptor in HER2-positive early breast cancer: Two different diseases?
First Author: Eva Maria Ciruelos Gil